Canadian Biotech Stock Surges on COVID-19 Vaccine Trial

Vaxil Bio Ltd. (TSXV:VXL), a Canadian biotech stock, jumped after starting a pre-clinical program for its COVID-19 vaccine candidate

Sean Mason | March 27, 2020 | SmallCapPower

A pre-clinical COVID-19 vaccine trial sparked much speculation in a Canadian biotech stock Friday. Here’s some small stocks making big moves on Friday, March 27, 2020 (as of 4 pm EST):

Vaxil Bio Ltd. (TSXV:VXL), a Canadian biotech stock, powered 30% higher to $0.195 on Friday after announcing that it has a non-GMP vaccine material in hand and has begun to execute its pre-clinical program to test the efficacy of the Company’s COVID-19 vaccine candidate. Vaxil Bio added that it has applied for an additional patent in connection with COVID-19.

Win Big With Our Small Cap Picks

 

As well, shares of Tinkerine Studios Ltd. (TSXV:TTD) gained 38% to $0.145 as the provider of 3D printing products said it has received initial orders for its Face Shield. As of official production and launch, the Company received interest of 4500+ Face Shield inquires over 24 hours.

K92 Mining Inc. (TSXV:KNT), meanwhile, reported that its Fiscal 2019 revenue surged 91% to US$101.7 million, while posting a record yearly profit of US$32.5 million, or US$0.16 per share. The Company also recorded AISC of US$680 per gold ounce for the year, exceeding its upgraded guidance of US$720-760/oz gold. K92 Mining stock moved up 3% to $3.07 following the announcement.

Related: K92 Mining Stock Should Continue to Shine

See more Small and Micro Cap Market Movers Daily from Sean Mason. Tomorrow’s big stock market winners could be found here today!

Hi, did you know SmallCapPower accepts blog submissions? You can contact me here

Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.

To read our full disclosure, please click on the button below: